BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35979528)

  • 1. Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States.
    Atallah EL; Maegawa R; Latremouille-Viau D; Rossi C; Guérin A; Wu EQ; Patwardhan P
    J Health Econ Outcomes Res; 2022; 9(2):19-29. PubMed ID: 35979528
    [No Abstract]   [Full Text] [Related]  

  • 2. Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis.
    Ito D; Feng C; Fu C; Kim C; Wu J; Dalton D; Epstein J; Snider JT; DuVall AS
    Clin Ther; 2024 Jan; 46(1):3-11. PubMed ID: 37981560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
    Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic Myeloid Leukemia: Part II-Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective.
    Atallah EL; Maegawa R; Latremouille-Viau D; Rossi C; Guérin A
    J Health Econ Outcomes Res; 2022; 9(2):30-36. PubMed ID: 35979529
    [No Abstract]   [Full Text] [Related]  

  • 5. Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims.
    Freedland SJ; Davis MR; Epstein AJ; Arondekar B; Ivanova JI
    Adv Ther; 2023 Oct; 40(10):4480-4492. PubMed ID: 37531024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
    Latremouille-Viau D; Guerin A; Gagnon-Sanschagrin P; Dea K; Cohen BG; Joseph GJ
    J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia.
    McGarry LJ; Chen YJ; Divino V; Pokras S; Taylor CR; Munakata J; Nieset CC; Huang H; Jabbour E; Malone DC
    Curr Med Res Opin; 2016; 32(2):289-99. PubMed ID: 26566171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States.
    Seiter K; Latremouille-Viau D; Guerin A; Ndife B; Habucky K; Tang DH; Pivneva I; Gagnon-Sanschagrin P; Joseph GJ
    Adv Ther; 2018 Oct; 35(10):1671-1685. PubMed ID: 30155792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
    Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis.
    Vanderpoel J; Emond B; Ghelerter I; Milbers K; Lafeuille MH; Lefebvre P; Ellis LA
    Pharmacoecon Open; 2023 Jul; 7(4):617-626. PubMed ID: 37074589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data.
    Swami U; Aggarwal H; Zhou M; Jiang S; Kim J; Li W; Laliberté F; Emond B; Agarwal N
    Clin Genitourin Cancer; 2023 Oct; 21(5):517-529. PubMed ID: 37248148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations.
    Stein EM; Bonifacio G; Latremouille-Viau D; Guerin A; Shi S; Gagnon-Sanschagrin P; Briggs O; Joseph GJ
    J Med Econ; 2018 Jun; 21(6):556-563. PubMed ID: 29304724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic burden of multiple myeloma among patients in successive lines of therapy in the United States.
    MacEwan JP; Batt K; Yin W; Peneva D; Sison S; Vine S; Chen C
    Leuk Lymphoma; 2018 Apr; 59(4):941-949. PubMed ID: 28805105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study.
    Ghosh N; Emond B; Lafeuille MH; Côté-Sergent A; Lefebvre P; Huang Q
    Clin Ther; 2021 Aug; 43(8):1285-1299. PubMed ID: 34332789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: A SEER-Medicare study.
    Shao C; He J; Kachroo S; Jin F
    Cancer Med; 2019 Dec; 8(18):7613-7622. PubMed ID: 31668011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of care and health care resource use among Medicaid-enrolled women with recurrent or metastatic cervical cancer.
    Leath CA; Nysenbaum J; Ting J; Zhang YJ; Fiori A; Pauly N
    J Manag Care Spec Pharm; 2023 May; 29(5):490-498. PubMed ID: 37121257
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States.
    Latremouille-Viau D; Guerin A; Nitulescu R; Gagnon PS; Joseph GJ; Chen L
    J Med Econ; 2017 Jan; 20(1):63-71. PubMed ID: 27603674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women.
    Gauthier G; Gagnon-Sanschagrin P; Guérin A; Burne R; Small T; Niravath P; Dalal AA
    Adv Ther; 2018 Apr; 35(4):503-514. PubMed ID: 29556908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.
    Lin J; Makenbaeva D; Lingohr-Smith M; Bilmes R
    J Med Econ; 2017 Jul; 20(7):687-691. PubMed ID: 28287043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase.
    Jabbour EJ; Lin J; Siegartel LR; Lingohr-Smith M; Menges B; Makenbaeva D
    J Med Econ; 2017 Sep; 20(9):1007-1012. PubMed ID: 28681664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.